Roles of Chk1 in cell biology and cancer therapy

被引:371
作者
Zhang, Youwei [1 ]
Hunter, Tony [2 ]
机构
[1] Case Western Reserve Univ, Dept Pharmacol, Case Comprehens Canc Ctr, Sch Med, Cleveland, OH 44106 USA
[2] Salk Inst Biol Studies, Mol & Cell Biol Lab, La Jolla, CA USA
关键词
Chk1; cell cycle checkpoints; cancer; cancer therapy; DNA-DAMAGE CHECKPOINT; S-PHASE CHECKPOINT; KINASE; CHK1; REPLICATION FORK PROGRESSION; PROTEIN-KINASE; MITOTIC FUNCTION; G2/M CHECKPOINT; MAMMALIAN CHK1; REGULATES CHK1; TARGETS CHK1;
D O I
10.1002/ijc.28226
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The evolutionally conserved DNA damage response (DDR) and cell cycle checkpoints preserve genome integrity. Central to these genome surveillance pathways is a protein kinase, Chk1. DNA damage induces activation of Chk1, which then transduces the checkpoint signal and facilitates cell cycle arrest and DNA damage repair. Significant progress has been made recently toward our understanding of Chk1 regulation and its implications in cancer etiology and therapy. Specifically, a model that involves both spatiotemporal and conformational changes of proteins has been proposed for Chk1 activation. Further, emerging evidence suggests that Chk1 does not appear to be a tumor suppressor; instead, it promotes tumor growth and may contribute to anticancer therapy resistance. Recent data from our laboratory suggest that activating, but not inhibiting, Chk1 in the absence of chemotherapy might represent an innovative approach to suppress tumor growth. These findings suggest unique regulation of Chk1 in cell biology and cancer etiology, pointing to novel strategies for targeting Chk1 in cancer therapy.
引用
收藏
页码:1013 / 1023
页数:11
相关论文
共 198 条
[1]   Regulation of mitotic entry by microcephalin and its overlap with ATR signalling [J].
Alderton, Gemma K. ;
Galbiati, Laura ;
Griffith, Elen ;
Surinya, Katharina H. ;
Neitzel, Heidemarie ;
Jackson, Andrew P. ;
Jeggo, Penny A. ;
O'Driscoll, Mark .
NATURE CELL BIOLOGY, 2006, 8 (07) :725-U157
[2]   IDENTIFICATION AND CHARACTERIZATION OF NEW ELEMENTS INVOLVED IN CHECKPOINT AND FEEDBACK CONTROLS IN FISSION YEAST [J].
ALKHODAIRY, F ;
FOTOU, E ;
SHELDRICK, KS ;
GRIFFITHS, DJF ;
LEHMANN, AR ;
CARR, AM .
MOLECULAR BIOLOGY OF THE CELL, 1994, 5 (02) :147-160
[3]   Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress [J].
Arlander, SJH ;
Eapen, AK ;
Vroman, BT ;
McDonald, RJ ;
Toft, DO ;
Karnitz, LM .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (52) :52572-52577
[4]   RNAi screening of the kinome identifies modulators of cisplatin response in ovarian cancer cells [J].
Arora, Shilpi ;
Bisanz, Kristen M. ;
Peralta, Lourdes A. ;
Basu, Gargi D. ;
Choudhary, Ashish ;
Tibes, Raoul ;
Azorsa, David O. .
GYNECOLOGIC ONCOLOGY, 2010, 118 (03) :220-227
[5]   Glioma stem cells promote radioresistance by preferential activation of the DNA damage response [J].
Bao, Shideng ;
Wu, Qiulian ;
McLendon, Roger E. ;
Hao, Yueling ;
Shi, Qing ;
Hjelmeland, Anita B. ;
Dewhirst, Mark W. ;
Bigner, Darell D. ;
Rich, Jeremy N. .
NATURE, 2006, 444 (7120) :756-760
[6]   Checking on DNA damage in S phase [J].
Bartek, J ;
Lukas, C ;
Lukas, J .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (10) :792-804
[7]   Therapeutic targeting of Chk1 in NSCLC stem cells during chemotherapy [J].
Bartucci, M. ;
Svensson, S. ;
Romania, P. ;
Dattilo, R. ;
Patrizii, M. ;
Signore, M. ;
Navarra, S. ;
Lotti, F. ;
Biffoni, M. ;
Pilozzi, E. ;
Duranti, E. ;
Martinelli, S. ;
Rinaldo, C. ;
Zeuner, A. ;
Maugeri-Sacca, M. ;
Eramo, A. ;
De Maria, R. .
CELL DEATH AND DIFFERENTIATION, 2012, 19 (05) :768-778
[8]   Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks [J].
Bekker-Jensen, S ;
Lukas, C ;
Kitagawa, R ;
Melander, F ;
Kastan, MB ;
Bartek, J ;
Lukas, J .
JOURNAL OF CELL BIOLOGY, 2006, 173 (02) :195-206
[9]   Checkpoint Signaling from a Single DNA Interstrand Crosslink [J].
Ben-Yehoyada, Merav ;
Wang, Lily C. ;
Kozekov, Ivan D. ;
Rizzo, Carmelo J. ;
Gottesman, Max E. ;
Gautier, Jean .
MOLECULAR CELL, 2009, 35 (05) :704-715
[10]   Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer [J].
Bennett, Christina N. ;
Tomlinson, Christine C. ;
Michalowski, Aleksandra M. ;
Chu, Isabel M. ;
Luger, Dror ;
Mittereder, Lara R. ;
Aprelikova, Olga ;
Shou, James ;
Piwinica-Worms, Helen ;
Caplen, Natasha J. ;
Hollingshead, Melinda G. ;
Green, Jeffrey E. .
BREAST CANCER RESEARCH, 2012, 14 (04)